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Abstract
Purpose: The aims of the study were: 1) to compare two phases of dual-phase cone beam computed tomography (DP-
CBCT) achieved before and after Yttrium-90 (90Y) administration and to evaluate additional benefits during radio-
embolisation (RE) procedures; and 2) to compare DP-CBCT with pre-procedure contrast enhanced cross-sectional 
images in terms of tumour detection.
Material and methods: Twenty-three hepatocellular carcinoma patients undergoing RE treatment were scanned with DP-
CBCT consisting of early arterial (EA) and late arterial (LA) phases before and after 90Y administration. The CT-like 
datasets were compared according to embolisation effect, enhancement patterns, lesion detectability, image quality, and 
artifacts by two interventional radiologists blinded to each other. The compatibility of the two radiologists was evaluated 
with kappa statistical analysis, and the difference between EA and LA phases was evaluated with marginal homogeneity 
test. Also, DP-CBCT images were compared with preprocedural cross-sectional images (CT/MRI).
Results: For 23 patients 92 data were acquired. Thirteen patients showed a decrease on post-embolisation images 
both visually and on Hounsfield unit (HU) measurements. No statistical difference was found for tumour detection 
between EA and LA phases (p = 1.0). Tumour enhancement was visually superior at LA phases whereas EA phases 
were better for arterial mapping for selective catheterisation. DP-CBCT images were not inferior to preprocedural 
cross-sectional imaging findings.
Conclusions: DP-CBCT is a promising tool for predicting tumour response to therapy and is not inferior to preproce-
dural cross-sectional imaging in terms of tumour detection. It allows better assessment during RE procedures because 
early phases provide good mapping for superselective catheterisation whereas late phases are better for visualisation 
of tumour enhancement.
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Introduction
Hepatocellular carcinoma (HCC) is the most common 
primary liver cancer and the third most common cause 
of cancer death worldwide [1,2]. The prognosis is poor 
due to delayed diagnosis and is one of the most common 
mortality causes in patients with cirrhosis [3,4]. Patients 
with high tumour load and/or comorbidities that are not 
suitable for surgery are treated with different system-
ic treatment options or local-regional therapies to de-
crease tumour load and improve the patient’s life quality 
and expectancy [5]. Radioembolisation (RE) is one of 
the optional regional therapies for inoperable HCC 
lesions where implantable radioactive microspheres 
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(Yttrium-90 [90Y]) are delivered to the feeding arteries. 
Like other intra-arterial procedures, RE has been eval-
uated for patients who are not eligible for resection or 
ablation, mostly with larger infiltrating and/or multifocal 
nodular tumours [6].
Cone beam computed tomography (CBCT) is a tech-
nology in which the C arm of the flat panel angiography 
rotates around the patient, acting as a CT detector provid-
ing data that can be reconstructed as cross-sectional CT 
images during interventional procedures [7]. The images 
acquired when the patient is on the table enable the in-
terventional radiologist to detect lesions that cannot be 
seen with routine catheter angiography [8]. CBCT is now 
widely used during liver tumour embolisation to ensure 
super selective catheterisation, thus avoiding non target 
embolisation, and to enhance detection of tumours that 
cannot be seen with routine catheter angiography [9]. 
It can provide information for evaluating the extra he-
patic leakage, parasitic feeders, portal vein invasion, and 
also for monitoring the embolisation effect [10]. One 
study showed improved survival rates in unresectable 
HCC patients when chemoembolisation is done with 
CBCT assistance [11]. In standard practice CBCT pro-
vides early arterial phase images. However, it has been 
shown that imaging of both early arterial (EA) and late 
arterial (LA) phases provides superior tumour detection 
than single-phase imaging [8,12,13]. So far, in the current 
English literature all studies of dual phase cone beam CT 
(DP-CBCT) have been made with transcatheter arterial 
chemoembolization (TACE) patient groups, and no study 
has ascertained whether DP-CBCT is a useful technology 
in detecting HCC nodules during RE. Therefore, in our 
study we aimed to demonstrate the feasibility of DP-CBCT 
with one contrast injection using a commercially available 
dual-run CBCT acquisition protocol software (syngo 
DynaCT, Siemens Healthcare) in HCC patients during 
RE. The purposes of the study were: 1) to compare two 
phases of DP-CBCT achieved before and after 90Y admin-
istration and evaluate additional benefits during RE pro-
cedures; and 2) to compare DP-CBCT with pre-procedure 
contrast-enhanced cross-sectional images in terms of tu-
mour detection.
Material and methods
This prospective study was approved by our institutional 
ethical committee, and informed consent was obtained 
from all patients. HCC patients referred to our interven-
tional unit for RE treatment were first evaluated regarding 
their performance status and liver functions, and the ones 
staged as Barcelona-Clinic Liver Cancer (BCLC) stage B 
and C were found to be eligible for RE treatment. From 
these patients, the ones who were considered capable 
of cooperation for the required breath holding and could 
tolerate mild sedation were enrolled in the study. 
Patients
There were a total of 23 either pathologically or radi-
ologically diagnosed HCC patients (four women, 19 
men), with a mean age of 64.9 ± 5.75 years (range 55-73). 
The etiology was hepatitis B virus (HBV) in 12 patients, 
hepatitis C virus (HCV) in two patients, and the rest had 
idiopathic chronic parenchymal disease. In two patients 
extra hepatic involvement was seen (portocaval-periceliac 
lymphadenopathy). Ten patients had portal vein throm-
bosis (four total, six partial). Ten patients had undergone 
a previous treatment; Sorafenib treatment (n = 1), system-
ic chemotherapy (n = 2), chemoembolisation procedure 
(n = 4), resection (n = 2), and resection-radiofrequency 
ablation and chemoembolisation (n = 1). 
Radioembolisation
After preprocedural evaluation of all laboratory and im-
aging findings, all patients first underwent angiographic 
assessment and Tc-99 labelled macro albumin aggregate 
(MAA) infusion for test angiography in which all neces-
sary gastrointestinal feeders were embolised, followed by 
MAA infusion for determining extra hepatic lung shunts 
and feeders to the gastrointestinal system. All patients 
were imaged with scintigraphy and/or single-photon 
emission-computed tomography (SPECT) CT within one 
hour of the test angiography, and all of them were found 
to be eligible for the treatment. One patient showed extra 
hepatic leakage towards the umbilicus through the falci-
form ligament. He was not excluded from the study but 
received the treatment under ice compression.
Radioembolisation with 90Y was performed within one 
month (mean 42.6 ± 18 days) of the MAA assessment. 
Treatment strategy of lobar or whole liver 90Y RE was de-
termined according to the extent of disease. A catheter 
was placed into the same location as during the MAA 
procedure, and glass microspheres were used for 90Y ad-
ministration. For each patient DP-CBCT was performed 
before and after 90Y infusion. Thus, out of 23 patients a to-
tal of 92 DP-CBCT datasets were gathered. After the pro-
cedure Bremsstrahlung imaging was performed within 
one hour to prove the absence of extra-hepatic leakage. 
All patients were discharged the following day with nor-
mal liver function. Laboratory and cross-sectional imag-
ing follow-up was done after one week, one month, and 
three months. 
Dual-phase cone-beam computed tomography technique
Dual-phase cone-beam CT imaging was performed on 
a flat-detector angiographic system (Artis zee Biplane, Sie-
mens Healthcare, Forchheim, Germany), which enabled 
CBCT acquisition and volumetric image reconstruction 
(Feldkamp back projection) according to the injection and 
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acquisition protocol shown in Figure 1. The DP-CBCT 
acquisition consisted of two runs: an initial rotation that 
captured the EA phase followed by a second rotation that 
captured the LA phase. The following parameters were 
used in data acquisition: acquisition time for each rotation 
approximately 5 s, 90 kV set kVp, detector entrance dose 
0.36 μGy/frame, 616 × 480 image matrix, projection on 
30 × 40 cm flat panel, 200° total angle, 0.8° angle incre-
ment/frame, and 248 frames in total.
A total volume of 36 ml of 25% diluted iodinated con-
trast medium (Ultravist-300, Bayer-Schering Pharma, 
Berlin, Germany) was injected through the 2.8 F coaxial 
microcatheter into the hepatic artery at a rate of 3 ml/s 
using a power injector (Medrad, Indianola, PA, USA) at 
300 psi for each DP-CBCT acquisition. 
Images were obtained as EA and LA phases respec-
tively at 6 s and 28 s with two breath holds (Figure 1). 
The projection data of each acquisition run was sent au-
tomatically to a dedicated workstation (syngo XWP, Sie-
mens Healthcare, Forchheim, Germany) on which CT-like 
axial slices with an isotropic voxel size of 0.5 mm were 
reconstructed for each phase. DP-CBCT imaging was 
performed for all 23 patients pre- and post-embolisation, 
resulting in 46 pairs of EA and LA phase images. These 
92 reconstructed CBCT series were evaluated using Multi 
Planar Reformat (MPR) or Maximum Intensity Projection 
(MIP) side by side.
Image analysis
Images were evaluated by two interventional radiologists 
(BP, 15 years and GE, five years of IR experience) blinded 
to each other. They were asked to classify and compare pre- 
and post-embolisation images regarding the following:
1. Embolisation effect: Although RE is less embolic 
comparing TACE, pre- and post-embolisation images 
were evaluated both visually and by Hounsfield unit 
(HU) measurements to see if there were any embo-
lisation effects that could be detected on tumour en-
hancement. Targeting a single lesion for multifocal 
tumours, and lobar and segmental lesions for each 
patient, pre-embolisation EA images were compared 
with post-embolisation EA images, and pre-embolisa-
tion LA images were compared with post-embolisa-
tion LA images.
2. Enhancement patterns: Pre-embolisation images were 
compared with basal cross-sectional images (CT/MRI) 
regarding tumoural contrast enhancement. Also, the 
two phases themselves were compared.
3. Lesion detectability: Comparison of each phase (EA 
and LA) of pre-embolisation images with preproce-
dural cross sectional images (CT/MRI) as well as the 
two phases with themselves was performed regarding 
lesion detectability. Lesions were categorised as dif-
fuse lobar, segmental, and multifocal. For infiltrative 
tumours lobar expansion and for multifocal tumours 
number of tumours were noted. 
4. Image quality: Pre-embolisation EA and LA phase 
CBCT images were evaluated for image quality and 
scaled as optimal (2 points), diagnostic (1 point), or 
non-diagnostic (0 point). 
5. Artifacts: Breath artifacts were assessed visually and 
also objectively by measuring maximum diaphragm 
movement in millimetres and its peak time on sagit-
tal plane from the raw data on pre-embolisation and 
post-embolisation early and late phases. Other artifacts 
that affected the image quality such as coils, lumen in 
the contrast, metallic artifacts, etc. were also noted.
Figure 1. The diagram showing the timing of the breath hold command and contrast injections in dual-phase C arm computed tomography technique
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Statistical analysis
The compatibility of the two radiologists was evalu-
ated with kappa statistical analysis for each parameter. 
The differences between early and late arterial phases was 
evaluated with marginal homogeneity test.
Results 
All 23 patients were successfully treated with RE without 
any complications, and the procedural success rate was 
100%. Eighteen patients received right lobar treatment, 
two patients received left lobar treatment, and three pa-
tients received whole liver treatment. Technical success for 
DP-CBCT was 100%. Performing a DP-CBCT acquisition 
pre- and post-radioembolisation in 23 patients, a total of 
92 CBCT datasets were acquired with dual-phase protocol 
both EA and LA phases (Figures 2 and 3) were performed 
with a single intra-arterial contrast infusion. 
Embolisation effect
Out of 23 patients, 21 were evaluated for embolisation 
effect. Two patients were excluded from this evaluation 
due to catheter displacement. Looking at two image se-
ries before and after embolisation, the following changes 
were noted visually and quantitatively. Thirteen patients 
showed a decrease on post-embolisation images both vis-
ually and on HU measurements. Four patients showed an 
increase in HU measurements. Four patients showed no 
difference visually between pre- and post-embolisation 
images. Of note, four total and four partial portal vein 
occlusions were found in these eight patients. Although 
visual changes were noted, the interobserver agreement 
was considered to be low, being 68% on early arterial 
phases and 35% on late arterial phases. No difference was 
found between early arterial and late arterial phases on 
the marginal homogeneity test within the image interpre-
tation of the two radiologists. 
Figure 2. Pre- and post-embolisation axial and coronal early arterial phase images
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Enhancement patterns
Both radiologists agreed that EA phases contrast enhance-
ment in the vessel lumen was prominent with a 100% con-
sistency in showing an arterial feeder mapping. Tumour en-
hancement was visually superior at LA phase to EA phase. 
When compared with cross-sectional images, dual-phase 
C-arm CT images were not found to be inferior regarding 
tumour enhancement except for one patient with a portal 
vein tumour, in whom cross-sectional images were found 
to be prominently superior in tumour enhancement. Con-
sistency between two radiologists was 100%. Of note, none 
of the tumours showed an area lacking enhancement that 
would be suspicious of an extrahepatic feeder. 
Lesion detectability
In ten patients – lobar involvement, in three patients – 
segmental involvement, and in nine patients – multifocal 
involvement was seen. One patient had a tumour in the 
portal vein lumen. All of the lesions’ characteristics were 
found to be the same with the preprocedural CT by both 
radiologists (sensitivity of lesion detection was 100%). Ac-
cording to lesion detectability, the two radiologists’ compat-
ibility was 100%. No difference was found in the marginal 
homogeneity test between EA and LA phases (p = 1.0).
Image quality
Pre-embolisation EA and LA phases were scored by two 
radiologists according to image quality, and the scores 
were summed as optimal (2 points), diagnostic (1 point), 
or non-diagnostic (0 point). Out of a total maximum 
score of 92 for 23 patients, EA phases total score was 69 
and LA phases score was 73, with a consistency between 
two radiologists of 96: 6% for early phase and 96% for 
delayed phases. The main factors affecting the image qual-
ity were patient arm positioning, obesity, and suboptimal 
patient positioning, among the ones scored as poor image 
quality. 
Figure 3. Pre- and post-embolisation axial and coronal late arterial phase images
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Artifacts
Measured from the raw data, the mean value of dia-
phragm motion was 5.4 mm (0-27 mm) on pre-emboli-
sation images and 3.28 mm (0-19 mm) on post-emboli-
sation images. The mean time of maximum motion was 
0.8 s on pre-embolisation images and 0.6 s on post-embo-
lisation images showing discordancy with the breath hold 
command given at the beginning of the scan. On visual 
assessment the consistency between the two radiologists 
was 86.2% for early phases and 88.1% for delayed phas-
es. No statistical difference was found between the two 
phases, and no accordance was found between visual and 
objective assessments statistically (p < 0.05) (first observer 
k = –0.037 and second observer k = –0.189).
All patients showed streak artifacts on early arterial 
phase images related to hepatic segmental vessels being 
filled with contrast, although the contrast used was diluted 
with saline. 
Other artifacts seen affecting the image quality were 
streak artifacts, caused by metallic clips and coils.
Discussion
In the literature, DP-CBCT was used for RE patients in 
only three studies previously. One of them was in a neuro-
endocrine patient group, one of them was with metastat-
ic disease, and the third was a case-report. Our study is 
the first one performed in HCC patients treated with 
RE. In the literature most of the studies are focused on 
chemoembolisation patient groups. Thus, these are the 
first outcomes of HCC patients treated with RE.
In HCC, tumour enhancement is known to be an 
indicator of active disease and is accepted as one of the 
tumour response criteria [14]. This led us to compare the 
images of pre and post 90Y infusion in terms of emboli-
sation effect, although RE is known to be less embolic 
than TACE. This is the first study comparing these two 
couples of CBCT data achieved during RE with HCC pa-
tients. Previous studies done with TACE easily pointed 
out the post-embolisation effect as an expected outcome 
of the embolic nature of TACE [15,16]. There is only one 
RE study on DP-CBCT using quantitative measurement 
methods, which involved a liver metastasis patient group 
using arbitrary units (AU), in the English language litera-
ture [17]. This study showed decreasing results in AU after 
RE. In our study in 13 patients the decrease was shown 
visually and quantitatively after RE. Although some differ-
ences were noted on the measurements, the interobserver 
agreement on visual correlation is low. CBCT measure-
ments may not be reproducible because HU measure-
ments have not been validated like multidetector CT HU 
measurements. Therefore, it should be considered that 
these changes may not be reflecting the true decrease of 
the tumour contrast enhancement. Furthermore, in our 
study four patients showed an increase in HU measure-
ments. These patients had a history of total or partial por-
tal vein thrombosis, which may have altered the liver per-
fusion. So as primary endpoint of our study, DP-CBCT is 
a promising technique to evaluate embolisation effect, but 
further studies are needed for quantitative measurements 
to foresee the treatment response periprocedurally.
The advantage of seeing the current tumour load on 
the day of treatment may be beneficial, especially in pa-
tients having a time gap between preprocedural cross sec-
tional imaging, MAA angiography, and RE procedures, 
and it may help prevent misinterpretation of treatment 
response on the third month post embolisation imaging. 
One of the reasons for early recurrence after intraarteri-
al treatments is failure to in detect small lesions during 
embolisation procedures. DSA and single-phase CBCT is 
inadequate in detection of small nodules [14,18].
The first studies to achieve more than one phase with 
CBCT were done with a totally different approach, with 
injections from two different locations: the hepatic artery 
injection for arterial phase, and superior mesenteric artery 
(SMA) injection for portography [7]. Miyayama et al. [9] 
achieved the two phases by two injections at different time 
points from the hepatic artery as an alternative to arteri-
oportography and found the sensitivity of lesion detecta-
bility to be 88.7%. However, for two separate injections, 
30-40 ml contrast media was used for each one. One of 
the highlights of our study is that it has the advantage of 
decreasing the amount of contrast media used by 50% be-
cause a single intra-arterial injection was enough to get 
two phases. The total amount of contrast media used in 
our study for dual imaging was 9 ml, which is also less than 
is used for cross-sectional CT imaging. 
The gathered data resulted in delineating the differ-
ences between using early and late arterial phases, having 
different advantages: EA phases showing hepatic arterial 
anatomy and LA phases showing better tumour enhance-
ment. In one study it was stated that DP-CBCT was able to 
change the intra-procedure decision and treatment strat-
egy in 38.6% of lesions [14]. One study performed with 
cholangiocellular carcinoma patients showed that lesions 
missed by digital subtraction angiography (DSA) were ei-
ther depicted by delayed arterial phase (95% completely 
and 5% partially) or early arterial phase (36.6% completely 
and 43.9% partially). Also, lesions missed by early-arterial 
phase (EAP) were depicted by delayed phase [18]. Another 
study with metastatic disease showed that missing lesions 
at early arterial phases were depicted by delayed phases 
[19]. In our study there was no statistical difference be-
tween EAP and LAP in terms of tumour detection because 
of big tumour burden. But tumour enhancement is found 
to be better in late arterial phases. 
For tumour detection, the acquisition protocol is very 
important. In the literature, for contrast injection param-
eters such as injection volume, injection rate, and contrast 
concentration (diluted/non-diluted), the scan time varies 
without any standard parameters. We performed two runs 
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with two breath holds at 6 s and 28 s. In some studies the 
first run was achieved at 3 s. In another study a second 
run was achieved at 18 s. In a study with HCC patients, 
two runs were achieved at 4.5 s and 55 s, respectively, and 
most of the small tumours were only depicted at EAP 
[14]. Also, it should be taken into consideration while pre-
paring the protocol that different types of tumours require 
different protocols. 
Our study results are in concordance with prior stud-
ies [8], showing that dual-phase imaging with CBCT can 
achieve enough information for lesion detection. Loffroy 
et al. [13] showed a sensitivity of 93.9% with dual-phase 
imaging compared to MRI in HCC lesions. Another re-
cent study performed with HCC patients who had un-
dergone TACE procedure showed that DP-CBCT tu-
mour detectability was noninferior to CT/MRI [20]. In 
our study the sensitivity of lesion detection was 100%; 
however, there were no significant differences in lesion 
detection compared to cross-sectional imaging, which can 
be explained because of the more advanced stage of the 
HCCs in our RE patient group. In general, RE is preferred 
for patients with more advanced stage HCCs that are not 
good candidates for TACE, and most of the previously 
published studies are based on chemoembolisation patient 
groups, which usually have smaller multifocal lesions and 
a lower tumour load. Being the first published study on 
an RE patient group when compared to basal cross-sec-
tional images, acquired DP-CBCT images were at least 
non-inferior to them, the one patient presenting with only 
portal vein thrombus being exceptional. When compared 
to cross-sectional CT, evaluation of non-parenchymal le-
sions such as portal tumoural thrombus CBCT showed 
a disadvantage. 
As a secondary endpoint of our study, DP-CBCT, im-
proved individualised treatment for each patient by being 
tumour selective and protective of the normal liver tissue. 
It allows the interventional radiologist not only to see the 
tumour burden but also helps in terms of arterial access 
for selective embolisation and intraprocedural evaluation 
of success.
There are some limitations to the study. First, the pa-
tient population was low for statistical evaluation. Second, 
the breathing artifacts caused some limitations. To prevent 
this issue, cooperating patients were included in the study, 
and lower sedative medication was used. Some studies 
with one breath hold can be found in the literature. Dur-
ing the procedure we gave two breath hold commands to 
maintain patient comfort in order to reduce motion arti-
facts. Based on our measurements, maximum breathing 
artifacts occurred at the beginning of the first rotation of 
the C-arm, showing that the patients were not coopera-
tive enough. Other artifacts that affected the image quality 
resulted from the contrast filling the lumen at the arterial 
phase. Loffroy et al. and Pellerin et al. used non-diluted 
contrast medium in their study and stated that it affected 
the image quality [13,21]. We also used diluted contrast 
media in our study.
Streak artifacts also deteriorated the image quality. 
Some can be avoided by positioning the patient’s arms 
above the abdomen or by taking the ECG cables off the 
patient [22]. However, some artifacts such as metallic coils 
in gastroduodenal and right gastric artery cannot be obvi-
ated. Development of software solutions for metal artifacts 
reduction, similar to the ones used in some multidetector 
computed tomography (MDCT) technologies, is needed. 
Despite all these artifacts, dual-phase CT achieved good 
image quality, at least diagnostically.
Another limitation of our study is that the radiation 
dose was not calculated. However, in the literature there 
are studies showing that CBCT causes lower radiation dos-
es than MDCT [8,13]. Also, a new study showed that in 
the radiation exposure during chemoembolisation, CBCT 
accounted for only 10% of the radiation exposure during 
the whole procedure using standard equipment [23].
Conclusions
In conclusion, knowing that CBCT is becoming a part 
of almost every interventional oncologic procedure, du-
al-phase imaging may give additional benefits during RE 
procedures. The future questions that could arise from 
this study are regarding detection of extrahepatic leakage 
with DP-CBCT and replacement with hepatic scintigra-
phy and prediction of survival outcomes of RE, which all 
need further detailed multi-centric studies.
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